Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07646717CT.gov Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma | — | Active Not Recruiting | — | — | — |
NCT07353827CT.gov FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma | — | Not Yet Recruiting | — | — | — |
NCT07328919CT.gov Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations | — | Not Yet Recruiting | — | — | — |
NCT06739252CT.gov Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA | — | Terminated | — | — | — |
NCT06648525CT.gov Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC | — | Not Yet Recruiting | — | — | — |
NCT05712356CT.gov A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03044587CT.gov Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Intrahepatic Cholangiocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluorouracilum (this asset) | Tianjin Medical University Cancer Institute and Hospital | P3 | B · 58 |
| Nivolumab | Virogin Biotech Canada Ltd | P2 | BB |
| Durvalumab | West China Hospital | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Shanghai 6th People's Hospital | P2 | BB |
| Atezolizumab | National Cancer Institute (NCI) | P2 | B |
| Irinotecan | Tianjin Medical University Cancer Institute and Hospital | P3 | B |
| Ipilimumab | TriSalus Life Sciences, Inc. | P2 | B |
| Lenvatinib | Tianjin Medical University Cancer Institute and Hospital | P2 | B |
| Pembrolizumab | Shanghai 6th People's Hospital | P1/2 | B |
+42 more in the Intrahepatic Cholangiocarcinoma cohort
Other indications for Fluorouracilum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 77 |
| Rectal Cancer | — | P3 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fluorouracilum in Intrahepatic Cholangiocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluorouracilum-intrahepatic-cholangiocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →